Your browser doesn't support javascript.
loading
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.
Johnson, Reed F; Bagci, Ulas; Keith, Lauren; Tang, Xianchun; Mollura, Daniel J; Zeitlin, Larry; Qin, Jing; Huzella, Louis; Bartos, Christopher J; Bohorova, Natasha; Bohorov, Ognian; Goodman, Charles; Kim, Do H; Paulty, Michael H; Velasco, Jesus; Whaley, Kevin J; Johnson, Joshua C; Pettitt, James; Ork, Britini L; Solomon, Jeffrey; Oberlander, Nicholas; Zhu, Quan; Sun, Jiusong; Holbrook, Michael R; Olinger, Gene G; Baric, Ralph S; Hensley, Lisa E; Jahrling, Peter B; Marasco, Wayne A.
Afiliación
  • Johnson RF; Emerging Viral Pathogens Section National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA. Electronic address: johnsonreed@mail.nih.gov.
  • Bagci U; Center for Infectious Disease Imaging, National Institutes of Health Clinical Center, Bethesda MD 20892, USA; Center for Research in Computer Vision (CRCV), Department of Electrics Electronics and Computer Science, University of Central Florida, Orlando, FL 32816, USA.
  • Keith L; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Tang X; Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Mollura DJ; Center for Infectious Disease Imaging, National Institutes of Health Clinical Center, Bethesda MD 20892, USA.
  • Zeitlin L; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Qin J; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Huzella L; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Bartos CJ; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Bohorova N; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Bohorov O; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Goodman C; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Kim DH; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Paulty MH; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Velasco J; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Whaley KJ; Mapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
  • Johnson JC; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Pettitt J; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Ork BL; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Solomon J; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research,Frederick, MD 21702-USA.
  • Oberlander N; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Zhu Q; Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Sun J; Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Holbrook MR; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Olinger GG; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Baric RS; Department of Microbiology and Immunology, Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Hensley LE; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Jahrling PB; Emerging Viral Pathogens Section National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
  • Marasco WA; Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Virology ; 490: 49-58, 2016 03.
Article en En | MEDLINE | ID: mdl-26828465
ABSTRACT
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×10(6) PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Infecciones por Coronavirus / Coronavirus del Síndrome Respiratorio de Oriente Medio / Pulmón / Anticuerpos Monoclonales / Anticuerpos Antivirales Límite: Animals / Humans / Male Idioma: En Revista: Virology Año: 2016 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Infecciones por Coronavirus / Coronavirus del Síndrome Respiratorio de Oriente Medio / Pulmón / Anticuerpos Monoclonales / Anticuerpos Antivirales Límite: Animals / Humans / Male Idioma: En Revista: Virology Año: 2016 Tipo del documento: Article